BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
5/8 — Partial
Priority Review
ELAHERE (mirvetuximab soravtansine) by AbbVie is soravtansine-gynx is an antibody-drug conjugate (adc). Approved for ovarian cancer, peritoneal cancer, fallopian tube cancer. First approved in 2022.
Drug data last refreshed 21h ago
Mechanism of Action
soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is…
Indications (3)
Worked on ELAHERE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.